Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2021 Feb 8;34(1):50–60. doi: 10.3967/bes2021.007

The Pathogenesis and Treatment of COVID-19: A System Review

Ye Long JI 1,&, Yang WU 1,&, Zhen QIU 1, Hao MING 1, Yi ZHANG 1, Ai Ning ZHANG 1, Yan LENG 1,#, Zhong Yuan XIA 1,#
PMCID: PMC7870101  PMID: 33531107

The content is available as a PDF (554.7 KB).

Biographies

Biographical notes of the first authors: JI Ye Long, male, born in 1995, bachelor degree, majoring in clinicalanesthesiology

WU Yang, male, born in 1980, MD, majoring in perioperative organ protection.

References

  • 1.Wang C, Horby P W, Hayden FG. A novel coronavirus outbreak of global health concern. Lancet. 2020;395:470–473. doi: 10.1016/S0140-6736(20)30185-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Huang CL, Wang YM, Li XW. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.World Health Organization WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. https://new.qq.com/omn/20200212/20200212A03TJD00.html [2020-02-11].
  • 4.World Health Organization WHO Director-General's opening remarks at the media briefing on COVID-19 - March 11 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020 [2020-03-11].
  • 5.World Health Organization WHO director-general's statement on IHR emergency committee on novel coronavirus (2019-nCoV) https://www.who.int/dg/speeches/detail/who-director-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov) [2020-01-30].
  • 6.Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol. 2016;3:237–261. doi: 10.1146/annurev-virology-110615-042301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Lu RJ, Zhao X, Li J. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574. doi: 10.1016/S0140-6736(20)30251-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Chinese Center for Disease Control Distribution of new coronavirus pneumonia] http://2019ncov.chinacdc.cn/2019-nCoV/global.html [2020-05-27]. (In Chinese)
  • 9.Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005;69:635–664. doi: 10.1128/MMBR.69.4.635-664.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Su S, Wong G, Shi WF. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24:490–502. doi: 10.1016/j.tim.2016.03.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181–192. doi: 10.1038/s41579-018-0118-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Song ZQ, Xu YF, Bao LL. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11:59. doi: 10.3390/v11010059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Li F. Receptor recognition mechanisms of coronaviruses: a decade of structural studies. J Virol. 2015;89:1954–1964. doi: 10.1128/JVI.02615-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Khailany RA, Safdar M, Ozaslan M. Genomic characterization of a novel SARS-CoV-2. Gene Rep. 2020;19 doi: 10.1016/j.genrep.2020.100682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Lan J, Ge JW, Yu JF. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215–220. doi: 10.1038/s41586-020-2180-5. [DOI] [PubMed] [Google Scholar]
  • 16.Tian SF, Hu WD, Niu L. Pulmonary pathology of early-phase 2019 Novel Coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020;15:700–704. doi: 10.1016/j.jtho.2020.02.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Xu Z, Shi L, Wang YJ. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–422. doi: 10.1016/S2213-2600(20)30076-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Xiao F, Tang MW, Zheng XB. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020;158:1831–1833. doi: 10.1053/j.gastro.2020.02.055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lauer SA, Grantz KH, Bi QF. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172:577–582. doi: 10.7326/M20-0504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Chen NS, Zhou M, Dong X. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Wang DW, Hu B, Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. doi: 10.1001/jama.2020.1585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Yang WJ, Cao QQ, Qin L. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020;80:388–393. doi: 10.1016/j.jinf.2020.02.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Guan WJ, Ni ZY, Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Li Q, Guan XH, Wu P. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–1207. doi: 10.1056/NEJMoa2001316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Jalava K. First respiratory transmitted food borne outbreak? Int J Hyg Environ Health. 2020;226 doi: 10.1016/j.ijheh.2020.113490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.National Health Commission of the People's Republic of China Diagnosis and treatment protocols of COVID-19 infection (7th edition) https://www.cma.org.cn/art/2020/3/4/art_2928_33242.html [2020-03-04]. (In Chinese)
  • 27.Kampf G, Todt D, Pfaender S. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104:246–251. doi: 10.1016/j.jhin.2020.06.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Kwok YL, Gralton J, McLaws ML. Face touching: a frequent habit that has implications for hand hygiene. Am J Infect Control. 2015;43:112–114. doi: 10.1016/j.ajic.2014.10.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Tian Y, Rong L, Nian WD. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 2020;51:843–851. doi: 10.1111/apt.15731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Zhou P, Yang XL, Wang XG. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi: 10.1038/s41586-020-2012-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Centers for Disease Control and Prevention Testing for COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html [2020-06-24]. [PubMed]
  • 32.Sahu KK, Mishra AK, Lal A. Comprehensive update on current outbreak of novel coronavirus infection (2019-nCoV) Ann Transl Med. 2020;8:393. doi: 10.21037/atm.2020.02.92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Nishiura H, Kobayashi T, Miyama T. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19) Int J Infect Dis. 2020;94:154–155. doi: 10.1016/j.ijid.2020.03.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Ai T, Yang ZL, Hou HY. Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020;296:E32–E40. doi: 10.1148/radiol.2020200642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Fang YC, Zhang HQ, Xie JC. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology. 2020;296:E115–E117. doi: 10.1148/radiol.2020200432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Chan JFW, Yip CCY, To KKW. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/hel real-time reverse transcription-PCR Assay validated in vitro and with clinical specimens. J Clin Microbiol. 2020;58:e00310–e00320. doi: 10.1128/JCM.00310-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Yang WJ, Sirajuddin A, Zhang XC. The role of imaging in 2019 novel coronavirus pneumonia (COVID-19) Eur Radiol. 2020;30:4874–4882. doi: 10.1007/s00330-020-06827-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Ye Z, Zhang Y, Wang Y. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol. 2020;30:4381–4389. doi: 10.1007/s00330-020-06801-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Some drugs for COVID-19. Med Lett Drugs Ther. 2020;62:49–50. [PubMed] [Google Scholar]
  • 40.Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ. 2020;368 doi: 10.1136/bmj.m1086. [DOI] [PubMed] [Google Scholar]
  • 41.Zeng YC, Cai ZX, Xianyu YY. Prognosis when using extracorporeal membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: a retrospective case series. Crit Care. 2020;24:148. doi: 10.1186/s13054-020-2840-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Ye Q, Wang BL, Mao JH. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020;80:607–613. doi: 10.1016/j.jinf.2020.03.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Bridgewood C, Damiani G, Sharif K. Rationale for evaluating PDE4 inhibition for mitigating against severe inflammation in COVID-19 pneumonia and beyond. Isr Med Assoc J. 2020;22:335–339. [PubMed] [Google Scholar]
  • 44.Damiani G, Pacifico A, Bragazzi NL. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during red-zone declaration. Dermatol Ther. 2020;1 doi: 10.1111/dth.13475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Han YY, Jiang M, Xia D. COVID-19 in a patient with long-term use of glucocorticoids: a study of a familial cluster. Clin Immunol. 2020;214 doi: 10.1016/j.clim.2020.108413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Shang LH, Zhao JP, Hu Y. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395:683–684. doi: 10.1016/S0140-6736(20)30361-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Long H, Nie L, Xiang XC. D-dimer and prothrombin time are the significant indicators of severe COVID-19 and poor prognosis. Biomed Res Int. 2020;2020 doi: 10.1155/2020/6159720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Thachil J, Tang N, Gando S. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18:1023–1026. doi: 10.1111/jth.14810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost. 2017;15:2099–2114. doi: 10.1111/jth.13813. [DOI] [PubMed] [Google Scholar]
  • 50.Yi Y, Lagniton PNP, Ye S. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci. 2020;16:1753–1766. doi: 10.7150/ijbs.45134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Garraud O, Heshmati F, Pozzetto B. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfus Clin Biol. 2016;23:39–44. doi: 10.1016/j.tracli.2015.12.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Parry RP, Tettmar KI, Hoschler K. Strategies for screening blood donors to source convalescent H1N1v plasma for intervention therapy. Vox Sang. 2012;103:107–112. doi: 10.1111/j.1423-0410.2012.01599.x. [DOI] [PubMed] [Google Scholar]
  • 53.Cheng Y, Wong R, Soo YO. use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44–46. doi: 10.1007/s10096-004-1271-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Arabi YM, Hajeer AH, Luke T. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, saudi arabia. Emerg Infect Dis. 2016;22:1554–1561. doi: 10.3201/eid2209.151164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Zhang B, Liu SY, Tan T. Treatment with convalescent plasma for critically Ill patients with severe acute respiratory syndrome coronavirus 2 infection. CHEST. 2020;158:e9–13. doi: 10.1016/j.chest.2020.03.039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Duan K, Liu BD, Li CS. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117:9490–9496. doi: 10.1073/pnas.2004168117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Shen CG, Wang ZQ, Zhao F. Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323:1582–1589. doi: 10.1001/jama.2020.4783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Lykkesfeldt J, Michels A J, Frei B. Vitamin C. Adv Nutr. 2014;5:16–18. doi: 10.3945/an.113.005157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Carr AC, Maggini S. Vitamin C and immune function. Nutrients. 2017;9 doi: 10.3390/nu9111211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Manning J, Mitchell B, Appadurai DA. Vitamin C promotes maturation of T-cells. Antioxid Redox Signal. 2013;19:2054–2067. doi: 10.1089/ars.2012.4988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Carr AC, Rosengrave PC, Bayer S. Hypovitaminosis C and vitamin C deficiency in critically ill patients despite recommended enteral and parenteral intakes. Crit Care. 2017;21:300. doi: 10.1186/s13054-017-1891-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013 doi: 10.1002/14651858.CD000980.pub4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Hemilä H, Chalker E. Vitamin C can shorten the length of stay in the ICU: a meta-analysis. Nutrients. 2019;11:708. doi: 10.3390/nu11040708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Hemilä H, Chalker E. Vitamin C may reduce the duration of mechanical ventilation in critically ill patients: a meta-regression analysis. J Intensive Care. 2020;8:15. doi: 10.1186/s40560-020-0432-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Liu PT, Stenger S, Li HY. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770–1773. doi: 10.1126/science.1123933. [DOI] [PubMed] [Google Scholar]
  • 66.Yang D, Chen Q, Schmidt AP. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med. 2000;192:1069–1074. doi: 10.1084/jem.192.7.1069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Martineau AR, Jolliffe DA, Hooper RL. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356 doi: 10.1136/bmj.i6583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Sharifi A, Vahedi H, Nedjat S. Effect of single-dose injection of vitamin D on immune cytokines in ulcerative colitis patients: a randomized placebo-controlled trial. APMIS. 2019;127:681–687. doi: 10.1111/apm.12982. [DOI] [PubMed] [Google Scholar]
  • 69.Topilski I, Flaishon L, Naveh Y. The anti-inflammatory effects of 1,25-dihydroxyvitamin D3 on Th2 cells in vivo are due in part to the control of integrin-mediated T lymphocyte homing. Eur J Immunol. 2004;34:1068–1076. doi: 10.1002/eji.200324532. [DOI] [PubMed] [Google Scholar]
  • 70.Xu J, Yang JL, Chen J. Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system. Mol Med Rep. 2017;16:7432–7438. doi: 10.3892/mmr.2017.7546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Vásárhelyi B, Sátori A, Olajos F. Low vitamin D levels among patients at Semmelweis University: retrospective analysis during a one-year period. Orv Hetil. 2011;152:1272–1277. doi: 10.1556/OH.2011.29187. [DOI] [PubMed] [Google Scholar]
  • 72.Rhodes JM, Subramanian S, Laird E. Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity. Aliment Pharmacol Ther. 2020;51:1434–1437. doi: 10.1111/apt.15777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Chen Z, Nakamura T. Statistical evidence for the usefulness of Chinese medicine in the treatment of SARS. Phytother Res. 2004;18:592–594. doi: 10.1002/ptr.1485. [DOI] [PubMed] [Google Scholar]
  • 74.Cinatl J, Morgenstern B, Bauer G. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003;361:2045–2046. doi: 10.1016/S0140-6736(03)13615-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Luo WS, Su XJ, Gong SJ. Anti-SARS coronavirus 3C-like protease effects of Rheum palmatum L. extracts. Biosci Trends. 2009;3:124–126. [PubMed] [Google Scholar]
  • 76.Lau KM, Lee KM, Koon CM. Immunomodulatory and anti-SARS activities of Houttuynia cordata. J Ethnopharmacol. 2008;118:79–85. doi: 10.1016/j.jep.2008.03.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Lin CW, Tsai FJ, Tsai CH. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res. 2005;68:36–42. doi: 10.1016/j.antiviral.2005.07.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Yu MS, Lee J, Lee JM. Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13. Bioorg Med Chem Lett. 2012;22:4049–4054. doi: 10.1016/j.bmcl.2012.04.081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Schwarz S, Sauter D, Wang K. Kaempferol derivatives as antiviral drugs against the 3a channel protein of coronavirus. Planta Med. 2014;80:177–182. doi: 10.1055/s-0033-1360277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Schwarz S, Wang K, Yu WJ. Emodin inhibits current through SARS-associated coronavirus 3a protein. Antiviral Res. 2011;90:64–69. doi: 10.1016/j.antiviral.2011.02.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.National Administration of Traditional Chinese Medicine National administration of traditional chinese medicine: explore the effect of qingfei paidu decoction on new coronary pneumonia. http://www.satcm.gov.cn/xinxifabu/meitibaodao/2020-02-17/13174.html [2020-02-17]. (In Chinese)
  • 82.Xia WG, an CQ, Zheng CJ. Clinical observation on 34 patients with novel coronavirus pneumonia (COVID-19) treated with intergrated traditional Chinese and western medicine. J Tradit Chin Med. 2020;61:375–382. (In Chinese) [Google Scholar]
  • 83.Perez EE, Orange JS, Bonilla F. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 2017;139:S1–46. doi: 10.1016/j.jaci.2016.09.023. [DOI] [PubMed] [Google Scholar]
  • 84.Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013;13:176–189. doi: 10.1038/nri3401. [DOI] [PubMed] [Google Scholar]
  • 85.Cao W, Liu XS, Bai T. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. 2020;7 doi: 10.1093/ofid/ofaa102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Mohtadi N, Ghaysouri A, Shirazi S. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: a case series. Virology. 2020;548:1–5. doi: 10.1016/j.virol.2020.05.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Xie Y, Cao S, Dong H. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect. 2020;81:318–356. doi: 10.1016/j.jinf.2020.03.044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Alijotas-Reig J, Esteve-Valverde E, Belizna C. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review. Autoimmun Rev. 2020;19 doi: 10.1016/j.autrev.2020.102569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Agnandji ST, Huttner A, Zinser ME. Phase 1 trials of rVSV ebola vaccine in africa and Europe. N Engl J Med. 2016;374:1647–1660. doi: 10.1056/NEJMoa1502924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Burki T. Ebola virus vaccine receives prequalification. Lancet. 2019;394 doi: 10.1016/S0140-6736(19)32905-8. [DOI] [PubMed] [Google Scholar]
  • 91.Zhang JY, Zeng H, Gu J. Progress and prospects on vaccine development against SARS-CoV-2. Vaccines (Basel) 2020;8:153. doi: 10.3390/vaccines8020153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Armengaud J, Delaunay-Moisan A, Thuret JY. The importance of naturally attenuated SARS-CoV-2in the fight against COVID-19. Environ Microbiol. 2020;22:1997–2000. doi: 10.1111/1462-2920.15039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Du LY, He YX, Zhou YS. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7:226–236. doi: 10.1038/nrmicro2090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Pardi N, Hogan MJ, Porter FW. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261–279. doi: 10.1038/nrd.2017.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Liu MA. A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines (Basel) 2019;7:37. doi: 10.3390/vaccines7020037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Zhu FC, Li YH, Guan XH. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395:1845–1854. doi: 10.1016/S0140-6736(20)31208-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Azmi F, Ahmad Fuaad AAH, Skwarczynski M. Recent progress in adjuvant discovery for peptide-based subunit vaccines. Hum Vaccin Immunother. 2014;10:778–796. doi: 10.4161/hv.27332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Sambhara S, Mcelhaney JE. Immunosenescence and influenza vaccine efficacy. In: Compans RW, Orenstein WA, editors. Vaccines for Pandemic Influenza. Springer; 2009. pp. 413–429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Tian XL, Li C, Huang AL. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;9:382–385. doi: 10.1080/22221751.2020.1729069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Plantone D, Koudriavtseva T. Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Investig. 2018;38:653–671. doi: 10.1007/s40261-018-0656-y. [DOI] [PubMed] [Google Scholar]
  • 101.Wang ML, Cao RY, Zhang LK. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. doi: 10.1038/s41422-020-0282-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Vincent MJ, Bergeron E, Benjannet S. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. doi: 10.1186/1743-422X-2-69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Yao XT, Ye F, Zhang M. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin Infect Dis. 2020;71:732–739. doi: 10.1093/cid/ciaa237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Gautret P, Lagier JC, Parola P. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56 doi: 10.1016/j.ijantimicag.2020.105949. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 105.Molina JM, Delaugerre C, Le Goff J. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50:384. doi: 10.1016/j.medmal.2020.03.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Tchesnokov EP, Feng JY, Porter DP. Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses. 2019;11:326. doi: 10.3390/v11040326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Sheahan TP, Sims AC, Graham RL. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9 doi: 10.1126/scitranslmed.aal3653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.De Wit E, Feldmann F, Cronin J. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA. 2020;117:6771–6776. doi: 10.1073/pnas.1922083117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.McCreary EK, Pogue JM. Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infect Dis. 2020;7 doi: 10.1093/ofid/ofaa105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Grein J, Ohmagari N, Shin D. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382:2327–2336. doi: 10.1056/NEJMoa2007016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Zumla A, Chan JFW, Azhar EI. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15:327–347. doi: 10.1038/nrd.2015.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.Chu CM, Cheng VCC, Hung IFN. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59:252–256. doi: 10.1136/thorax.2003.012658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Wang ZW, Chen XR, Lu YF. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020;14:64–68. doi: 10.5582/bst.2020.01030. [DOI] [PubMed] [Google Scholar]
  • 114.Cao B, Wang YM, Wen DN. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787–1799. doi: 10.1056/NEJMoa2001282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.World Health Organization Coronavirus disease (COVID-19) advice for the public. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public [2020-04-29].
  • 116.Centers for Disease Control and Prevention Recommendation regarding the use of cloth face coverings, especially in areas of significant community-based transmission. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover.html [2020-04-03].
  • 117.Bragazzi NL, Dai HJ, Damiani G. How big data and artificial intelligence can help better manage the COVID-19 pandemic. Int J Environ Res Public Health. 2020;17 doi: 10.3390/ijerph17093176. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biomedical and Environmental Sciences are provided here courtesy of Elsevier

RESOURCES